Artificial Intelligence in the Evaluation of Abnormal Liver Tests and MASLD: Emerging Applications in Risk Stratification and Clinical Decision Support
Downloads
DOI:
https://doi.org/10.71079/ASIDE.IM.081926834Abstract
Background: Abnormal liver tests and metabolic dysfunction-associated steatotic liver disease (MASLD) are common, yet the central clinical task is identifying advanced fibrosis, cirrhosis, or an alternative liver disease that requires timely investigation or referral.
Methods: We conducted a narrative review of PubMed, Ovid MEDLINE, Embase, Scopus, and Web of Science from database inception through April 2026, supplemented by searches of Google Scholar, reference lists, and relevant society guidelines.
Results: Artificial intelligence (AI) can integrate clinical, laboratory, longitudinal, imaging, and elastography data to support risk stratification, identify missing investigations, and assist referral workflows. Representative studies reported promising discrimination for selected outcomes, but populations, reference standards, and validation methods were heterogeneous; calibration and external validation were often absent or incompletely reported. Clinical use should begin with standard pattern recognition, exclusion of competing etiologies and urgent red flags, and age-aware interpretation of the fibrosis-4 index before second-line testing or referral.
Conclusions: AI is an emerging adjunct, not a replacement for clinical judgment. Evidence that it improves outcomes, reduces missed advanced fibrosis, or increases referral efficiency remains limited. Responsible adoption requires transparent models, clinician verification, external validation, calibration, workflow evaluation, and post-deployment monitoring.
Keywords:
Artificial intelligence, Abnormal liver tests, Liver fibrosis, Machine learning, Fibrosis risk stratificationReferences
1. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6–19. PMID: 29122851. https://doi.org/10.1136/gutjnl-2017-314924 DOI: https://doi.org/10.1136/gutjnl-2017-314924
2. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. PMID: 36727674. https://doi.org/10.1097/HEP.0000000000000323 DOI: https://doi.org/10.1097/HEP.0000000000000323
3. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. PMID: 36626630. https://doi.org/10.1097/HEP.0000000000000004 DOI: https://doi.org/10.1097/HEP.0000000000000004
4. Younossi ZM, Golabi P, Price JK, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999–2010. PMID: 38521116. https://doi.org/10.1016/j.cgh.2024.03.006 DOI: https://doi.org/10.1016/j.cgh.2024.03.006
5. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. PMID: 28130788. https://doi.org/10.1002/hep.29085 DOI: https://doi.org/10.1002/hep.29085
6. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67(11):2375–92. PMID: 38869512. https://doi.org/10.1007/s00125-024-06196-3 DOI: https://doi.org/10.1007/s00125-024-06196-3
7. Ghandian S, Thapa R, Garikipati A, et al. Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis. JGH Open. 2022;6(3):196–204. PMID: 35355667. https://doi.org/10.1002/jgh3.12716 DOI: https://doi.org/10.1002/jgh3.12716
8. Thrift AP, Nguyen Wenker TH, Godwin K, et al. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024;69(7):2430–6. PMID: 38700632. https://doi.org/10.1007/s10620-024-08437-2 DOI: https://doi.org/10.1007/s10620-024-08437-2
9. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18–35. PMID: 27995906. https://doi.org/10.1038/ajg.2016.517 DOI: https://doi.org/10.1038/ajg.2016.517
10. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022;163(3):764–74. PMID: 35842345. https://doi.org/10.1053/j.gastro.2022.06.023 DOI: https://doi.org/10.1053/j.gastro.2022.06.023
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. 2021;75(3):659–89. PMID: 34166721. https://doi.org/10.1016/j.jhep.2021.05.025 DOI: https://doi.org/10.1016/j.jhep.2021.05.025
12. Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2023;165(4):1080–8. PMID: 37542503. https://doi.org/10.1053/j.gastro.2023.06.013 DOI: https://doi.org/10.1053/j.gastro.2023.06.013
13. Wong GL, Yuen PC, Ma AJ, et al. Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. J Gastroenterol Hepatol. 2021;36(3):543–50. PMID: 33709607. https://doi.org/10.1111/jgh.15385 DOI: https://doi.org/10.1111/jgh.15385
14. Aggarwal P, Alkhouri N. Artificial Intelligence in Nonalcoholic Fatty Liver Disease: A New Frontier in Diagnosis and Treatment. Clin Liver Dis (Hoboken). 2021;17(6):392–7. PMID: 34386201. https://doi.org/10.1002/cld.1071 DOI: https://doi.org/10.1002/cld.1071
15. Goldman O, Ben-Assuli O, Rogowski O, et al. Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. J Med Syst. 2021;45(2):22. PMID: 33426569. https://doi.org/10.1007/s10916-020-01693-5 DOI: https://doi.org/10.1007/s10916-020-01693-5
16. Mamandipoor B, Wernly S, Semmler G, et al. Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study. Clin Res Hepatol Gastroenterol. 2023;47(7):102181. PMID: 37467893. https://doi.org/10.1016/j.clinre.2023.102181 DOI: https://doi.org/10.1016/j.clinre.2023.102181
17. Kalka IN, Hazzan R, Yacovzada NS, et al. Fibro: a machine learning risk score for advanced liver fibrosis in the general population using Israeli electronic health records. Sci Rep. 2025;15(1):32035. PMID: 40887472. https://doi.org/10.1038/s41598-025-17534-9 DOI: https://doi.org/10.1038/s41598-025-17534-9
18. Njei B, Osta E, Njei N, et al. An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis. Sci Rep. 2024;14(1):8589. PMID: 38615137. https://doi.org/10.1038/s41598-024-59183-4 DOI: https://doi.org/10.1038/s41598-024-59183-4
19. Kosick HM, McIntosh C, Bera C, et al. Machine learning models using non-invasive tests and B-mode ultrasound to predict liver-related outcomes in metabolic dysfunction-associated steatotic liver disease. Sci Rep. 2025;15(1):24579. PMID: 40628914. https://doi.org/10.1038/s41598-025-09288-1 DOI: https://doi.org/10.1038/s41598-025-09288-1
20. Destrempes F, Gesnik M, Chayer B, et al. Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. PLoS One. 2022;17(1):e0262291. PMID: 35085294. https://doi.org/10.1371/journal.pone.0262291 DOI: https://doi.org/10.1371/journal.pone.0262291
21. Shroff H, Shankar A, Baron A, et al. A Large Language Model Assistant for Summarizing Hepatology Referral Documents. Am J Gastroenterol. 2026;121(4):925–31. PMID: 41504326. https://doi.org/10.14309/ajg.0000000000003905 DOI: https://doi.org/10.14309/ajg.0000000000003905
22. Nam D, Chapiro J, Paradis V, et al. Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction. JHEP Rep. 2022;4(4):100443. PMID: 35243281. https://doi.org/10.1016/j.jhepr.2022.100443 DOI: https://doi.org/10.1016/j.jhepr.2022.100443
23. Li J, Chen J, Zeng X, et al. Update of machine learning for ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a bright future for deep learning. PeerJ. 2025;13:e19645. PMID: 40611943. https://doi.org/10.7717/peerj.19645 DOI: https://doi.org/10.7717/peerj.19645
24. Ahn JC, Connell A, Simonetto DA, et al. Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases. Hepatology. 2021;73(6):2546–63. PMID: 33098140. https://doi.org/10.1002/hep.31603 DOI: https://doi.org/10.1002/hep.31603
25. Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. PMID: 38626948. https://doi.org/10.1136/bmj-2023-078378 DOI: https://doi.org/10.1136/bmj-2023-078378
26. Kelly CJ, Karthikesalingam A, Suleyman M, et al. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. PMID: 31665002. https://doi.org/10.1186/s12916-019-1426-2 DOI: https://doi.org/10.1186/s12916-019-1426-2
27. Obermeyer Z, Powers B, Vogeli C, et al. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447–53. PMID: 31649194. https://doi.org/10.1126/science.aax2342 DOI: https://doi.org/10.1126/science.aax2342
28. Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. BMJ. 2022;377:e070904. PMID: 35584845. https://doi.org/10.1136/bmj-2022-070904 DOI: https://doi.org/10.1136/bmj-2022-070904
29. Ning Y, Teixayavong S, Shang Y, et al. Generative artificial intelligence and ethical considerations in health care: a scoping review and ethics checklist. Lancet Digit Health. 2024;6(11):e848–56. PMID: 39294061. https://doi.org/10.1016/S2589-7500(24)00143-2 DOI: https://doi.org/10.1016/S2589-7500(24)00143-2
30. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898–906. PMID: 15940625. https://doi.org/10.1053/j.gastro.2005.03.084 DOI: https://doi.org/10.1053/j.gastro.2005.03.084
31. Liu X, Cruz Rivera S, Moher D, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat Med. 2020;26(9):1364–74. PMID: 32908283. https://doi.org/10.1038/s41591-020-1034-x DOI: https://doi.org/10.1038/s41591-020-1034-x
Data Availability Statement
No new datasets were generated or analyzed for this narrative review. All data discussed are derived from previously published studies cited in the manuscript.
License
Copyright (c) 2026 Ahmed Salman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Licensing
All articles published in ASIDE Internal Medicine are open access and freely available online immediately upon publication, without embargo.
This journal applies the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, anyone may copy, redistribute, remix, transform, and build upon the material for any purpose, even commercially, provided that proper credit is given to the original author(s), a link to the license is provided, and any changes made are indicated.
-
License link: https://creativecommons.org/licenses/by/4.0/
-
Machine-readable license metadata is embedded in each article and its DOI record.
Copyright Holder
Copyright in all articles remains with the author(s). By submitting a manuscript, authors agree to grant the publisher (American Society for Inclusion, Diversity, and Equity in Healthcare – ASIDE) a non-exclusive license to publish and distribute the work under the terms of the CC BY 4.0 license.
Third-party Material
Any material (e.g., images, figures, or tables) not covered by CC BY 4.0 will be clearly indicated in the article. Users must obtain permission directly from the copyright holder for reuse of such third-party material.
Author Rights and Self-Archiving
Authors are permitted to deposit all versions of their work (preprint, author’s accepted manuscript, and version of record) in institutional or subject repositories of their choice immediately upon publication, without embargo, provided that the DOI and license information are included.
Downloads
Published
Issue
Section
Categories
How to Cite
Article history
- Received
- 8 May 2026
- Received in revised form
- 23 Jul 2026
- Accepted
- 30 Jul 2026
- Published
- 19 Aug 2026
